| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/05/2012 | US20120004201 Phosphodiestarase inhibitors |
| 01/05/2012 | US20120004200 Topical pharmaceutical composition containing a water-sensitive active principle |
| 01/05/2012 | US20120004195 Cyclodextrin-based polymers for therapeutic delivery |
| 01/05/2012 | US20120004191 Combinational Compositions And Methods For Treatment Of Cancer |
| 01/05/2012 | US20120004184 Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2 |
| 01/05/2012 | US20120004182 Pharmaceutical compositions and methods for induction and enhancement of apoptosis in tumor cells |
| 01/05/2012 | US20120004181 Targeted delivery system |
| 01/05/2012 | US20120004177 Compositions and methods of delivery of pharmacological agents |
| 01/05/2012 | US20120004175 Inhibitors of nf-kb activity |
| 01/05/2012 | US20120004169 Materials and methods for treatment of cancer and identification of anti-cancer compounds |
| 01/05/2012 | US20120003629 Biological control of nanoparticle nucleation, shape and crystal phase |
| 01/05/2012 | US20120003340 Compositions and methods for detoxification and cancer prevention |
| 01/05/2012 | US20120003337 Health supplements containing phyto-oestrogens, analogues or metabolites thereof |
| 01/05/2012 | US20120003330 Benzoquinolone inhibitors of vmat2 |
| 01/05/2012 | US20120003327 Method of reducing multi-drug resistance using inositol tripyrophosphate |
| 01/05/2012 | US20120003309 Solid Dosage Forms Of Bendamustine |
| 01/05/2012 | US20120003305 Oral Dosage Forms Of Bendamustine |
| 01/05/2012 | US20120003302 Pharmaceutical composition containing a fermented, dehydrated material with amorphous crystalline structure |
| 01/05/2012 | US20120003299 Novel hsp90-targeted anti-cancer chimeric peptide |
| 01/05/2012 | US20120003297 Compositions and methods for treating lymphoma |
| 01/05/2012 | US20120003295 Lipid a and other carbohydrate ligand analogs |
| 01/05/2012 | US20120003294 Fixed ratio camptothecens/platinum agents |
| 01/05/2012 | US20120003285 Method for manufacturing capsule series, and related capsule series |
| 01/05/2012 | US20120003278 Single-walled carbon nanotube/sirna complexes and methods related thereto |
| 01/05/2012 | US20120003270 6-substituted isoflavonoid compounds and uses thereof |
| 01/05/2012 | US20120003268 Synergistic combination and method thereof |
| 01/05/2012 | US20120003262 Anticancer health food containing phellinus linteus and vegetable worms |
| 01/05/2012 | US20120003259 Molecule |
| 01/05/2012 | US20120003254 Breast Cancer Vaccine |
| 01/05/2012 | US20120003253 C1orf59 peptides and vaccines including the same |
| 01/05/2012 | US20120003252 Isoforms of human somatostatin receptor type 5 produced by alternative processing and oligo-nucleotide pairs for detection thereof by pcr |
| 01/05/2012 | US20120003251 Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes |
| 01/05/2012 | US20120003249 Immuno-molecules containing viral proteins, compositions thereof and methods of using |
| 01/05/2012 | US20120003248 Monomethylvaline compounds capable of conjugation to ligands |
| 01/05/2012 | US20120003247 Monomethylvaline compounds capable of conjugation to ligands |
| 01/05/2012 | US20120003236 Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins |
| 01/05/2012 | US20120003235 Anti-lymphotoxin antibodies |
| 01/05/2012 | US20120003232 Use of antibodies for the vaccination against cancer |
| 01/05/2012 | US20120003224 ANGIOGENIC AND IMMUNOLOGIC APPLICATIONS OF ANTI-CD160 SPECIFIC COMPOUNDS OBTAINABLE FROM mAb CL1-R2 |
| 01/05/2012 | US20120003223 Recombinant fusion protein and polynucleotide construct for immunotoxin production |
| 01/05/2012 | US20120003221 Human serum albumin linkers and conjugates thereof |
| 01/05/2012 | US20120003219 Compositions and Methods to Treat Bone Related Disorders |
| 01/05/2012 | US20120003217 Herceptin® aduvant therapy |
| 01/05/2012 | US20120003213 Methods Of Enhancing Antibody-Dependent Cellular Cytotoxicity |
| 01/05/2012 | US20120003209 Methods and kits used in identifying glioblastoma |
| 01/05/2012 | US20120003208 Compositions and methods for modulating vascular development |
| 01/05/2012 | US20120003207 Methods and compositions for modulating proline levels |
| 01/05/2012 | US20120003204 Composition containing arazyme for the prevention and treatment of cander |
| 01/05/2012 | US20120003181 Novel Retinoid Inducible Factor and Uses Thereof |
| 01/05/2012 | US20120003179 Anti-ctla-4 and cpg-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment |
| 01/05/2012 | US20120003177 Curcumin-containing polymers and water-soluble curcumin derivatives as prodrugs of prodrug carriers |
| 01/05/2012 | US20120003161 Use of inositol-tripyrophosphate in treating tumors and diseases |
| 01/05/2012 | US20120003157 Use of anti-90k monoclonal antibodies for the prevention and treatment of tumors and metastases thereof |
| 01/05/2012 | US20120003156 Methods for treating neoplasia by inhibiting lactate dehydrogenase and/or nicotinamide phosphoribosyltransferase |
| 01/05/2012 | US20120003150 Therapeutic ribonucleases |
| 01/05/2012 | US20120003149 Novel monoclonal antibody, and use thereof |
| 01/05/2012 | US20120003148 Radioimmunotherapy and imaging of tumor cells that express viral antigens |
| 01/05/2012 | DE102010025972A1 Determining protease in biological sample, comprises converting proform of protease into active protease, contacting test sample with substrate, at which inhibitor binding substance is bound and separating substrate with protease inhibitor |
| 01/05/2012 | DE102010025970A1 Verfahren zur Bestimmung von Proteasen und ihren Proformen A method for the determination of proteases and their pro-forms |
| 01/05/2012 | DE102010025786A1 Pyrazolochinoline Pyrazolochinoline |
| 01/05/2012 | CA2811061A1 Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor |
| 01/05/2012 | CA2810746A1 Method for preventing or treating skin tumor |
| 01/05/2012 | CA2804760A1 Single-walled carbon nanotube/sirna complexes and methods related thereto |
| 01/05/2012 | CA2804347A1 Heterocyclic alkynyl benzene compounds and medical compositions and uses thereof |
| 01/05/2012 | CA2804225A1 Heterocyclic compound and p27kip1 degradation inhibitor |
| 01/05/2012 | CA2804069A1 Pyrazoloquinolines |
| 01/05/2012 | CA2803879A1 Compositions and methods for modulating the wnt signaling pathway |
| 01/05/2012 | CA2803665A1 2,4- diaryl - substituted [1,8] naphthyridines as kinase inhibitors for use against cancer |
| 01/05/2012 | CA2803646A1 Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof |
| 01/05/2012 | CA2803624A1 Heterocyclic compounds and their use as inhibitors of pi3k activity |
| 01/05/2012 | CA2803620A1 Heterocyclic compounds and their uses |
| 01/05/2012 | CA2803478A1 Novel tetrahydroquinoline derivatives |
| 01/05/2012 | CA2803446A1 Methods of targeting pten mutant diseases and compositions therefor |
| 01/05/2012 | CA2803358A1 Heterocyclic compounds and their use as inhibitors of pi3k activity |
| 01/05/2012 | CA2803259A1 Heterocyclic compounds and their use as inhibitors of pi3k activity |
| 01/05/2012 | CA2802768A1 Recombinant tumor vaccine and method of producing such vaccine |
| 01/05/2012 | CA2801814A1 Quinazoline compounds |
| 01/04/2012 | EP2402373A2 Anti-EphB4 Antibodies and Methods Using Same |
| 01/04/2012 | EP2402372A2 Therapeutic agent |
| 01/04/2012 | EP2402349A1 Tricyclic pyrazolopyrimidine derivative |
| 01/04/2012 | EP2402347A1 Pharmaceutical compounds |
| 01/04/2012 | EP2402334A1 Inhibitors of E1 Activating Enzymes |
| 01/04/2012 | EP2402325A2 Hydroxylated and methoxylated cyclopenta[d]pyrimidines as AKT protein kinase inhibitors |
| 01/04/2012 | EP2402323A2 Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases |
| 01/04/2012 | EP2402036A1 Cyclodextrin-based polymers for delivering the therapeutic agents covalently attached thereto |
| 01/04/2012 | EP2402033A1 Cell adhesion inhibitor and use thereof |
| 01/04/2012 | EP2402031A1 Immunologic adjuvant composition and use thereof |
| 01/04/2012 | EP2402002A1 Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy |
| 01/04/2012 | EP2401301A2 Apparatus, system, and method for creating immunologically enhanced spaces in-vivo |
| 01/04/2012 | EP2401299A1 Anti-icam-1 antibody, uses and methods |
| 01/04/2012 | EP2401285A1 Complexes of 4-hydroperoxy ifosfamide as anti-tumor agents |
| 01/04/2012 | EP2401283A1 6-phenyl-2-ý((piperidin-4-ylmethyl)-piperazin-1yl) or piperazin 1-ylmethyl)-piperidin-1-yl)¨-imidazoý2,1-b¨ý1,3,4¨thiadiazole derivatives and their use |
| 01/04/2012 | EP2401281A1 Pyrimidopyrimidoindazole derivative |
| 01/04/2012 | EP2401267A1 Jak kinase modulating quinazoline derivatives and methods of use thereof |
| 01/04/2012 | EP2401251A2 Guanidino-substituted bi- and polyphenyls as small molecule carriers |
| 01/04/2012 | EP2400985A2 Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor |
| 01/04/2012 | EP2400979A2 Compositions and methods for visualizing and eliminating cancer stem cells |
| 01/04/2012 | EP2400965A1 Sigma( ) receptors ligands with anti-apoptotic and/or pro-apoptotic properties, over cellular mechanisms, exhibiting prototypical cytoprotective and also anticancer activity |
| 01/04/2012 | EP2400964A1 Crystalline n-{(1-s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride |
| 01/04/2012 | EP2400962A1 Drug combinations containing pde4 inhibitors and nsaids |